Enliven Therapy Drug ELVN-001 Poised to Disrupt Leukemia Treatment Market, Analyst Bullish

Enliven Therapeutics Inc. received an Outperform rating from William Blair on Tuesday, which initiated coverage, citing the potential of its lead drug candidate ELVN-001 to reshape the treatment landscape for chronic myeloid leukemia.

ELVN-001 Shows Positive Phase 1 Data

Enliven Therapeutics' lead drug, ELVN-001, is a small-molecule kinase inhibitor designed to specifically target the BCR::ABL1 gene fusion, the oncogenic driver of CML.

In June, the company reported positive data from its ongoing Phase 1 ENABLE clinical trial, which evaluates ELVN-001 in previously treated CML patients.

The data showed an overall major molecular response of 61% in the 80 mg once-daily Phase 1b cohort, with a 48% MMR rate at 24 weeks.

Response rates were higher in earlier-line patients, with an overall MMR of 67% in patients with only one or two prior distinct tyrosine kinase inhibitors, and 55% achieving MMR at 24 weeks.

Enliven Therapeutics Cash Reserves to Sustain Through 2030

As of June 30, 2026, the company held cash, cash equivalents, and marketable securities totaling $895.2 million, which is expected to provide a cash runway through 2030.

William Blair noted that ELVN-001 has the potential to serve patients across the treatment continuum, with an initial focus on the growing late-line patient population, followed by expansion into earlier treatment settings.

William Blair Bullish on $8.8 Billion CML Market

Analyst Andy Hsieh wrote that despite multiple approved CML tyrosine kinase inhibitors on the market, unmet medical needs remain, as a growing number of late-line patients seek more effective, better-tolerated, and more convenient treatment options.

William Blair estimates the current total addressable market for CML at approximately $8.8 billion, with the U.S. market at $5.6 billion.

The analyst also noted that at the planned Phase 3 dose level, the 48% MMR achievement rate is twice the rate demonstrated by Novartis AG's Scemblix, the current market leader.

Additionally, ELVN-001 is the only TKI shown to have activity against newly emerging resistance mutations to Scemblix treatment.

The analyst stated that ELVN-001 could disrupt the chronic myeloid leukemia treatment landscape, citing its differentiated profile and potential to serve patients across multiple treatment lines.

ELVN stock performance: As of Tuesday's data release, Enliven shares were down 3.80% at $1.52.